The stock of Esperion Therapeutics Inc. (NASDAQ:ESPR) last traded at $2.51, up 0.80% from the previous session.
ESPR stock price is now 6.39% away from the 50-day moving average and 24.78% away from the 200-day moving average. The market capitalization of the company currently stands at $427.75M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $2.50, BofA Securities recently Downgraded its rating from Neutral to Underperform for Esperion Therapeutics Inc. (NASDAQ: ESPR). , while ‘JP Morgan’ rates the stock as ‘Neutral’
In other news, Foody Joanne M., Chief Medical Officer sold 3,285 shares of the company’s stock on Jun 18 ’24. The stock was sold for $9,418 at an average price of $2.87. Upon completion of the transaction, the Chief Medical Officer now directly owns 273,779 shares in the company, valued at $0.69 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 18 ’24, Chief Commercial Officer Warren Eric sold 2,540 shares of the business’s stock. A total of $7,254 was realized by selling the stock at an average price of $2.86. This leaves the insider owning 165,586 shares of the company worth $0.42 million. A total of 9.23% of the company’s stock is owned by insiders.
During the past 12 months, Esperion Therapeutics Inc. has had a low of $0.70 and a high of $3.40. The fifty day moving average price for ESPR is $2.37 and a two-hundred day moving average price translates $2.01925 for the stock.
The latest earnings results from Esperion Therapeutics Inc. (NASDAQ: ESPR) was released for 2024-03-31. The company reported revenue of $137.74 million for the quarter, compared to $24.33 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 466.14 percent.
